Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: melanocortin receptor modulators - Palatin Technologies

Drug Profile

Research programme: melanocortin receptor modulators - Palatin Technologies

Alternative Names: PL-9610; PT 18

Latest Information Update: 28 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Palatin Technologies
  • Class Anti-inflammatories; Antihyperglycaemics; Eye disorder therapies; Obesity therapies; Peptides; Skin disorder therapies; Small molecules
  • Mechanism of Action Melanocortin receptor agonists; Melanocortin type 1 receptor agonists; Melanocortin type 3 receptor agonists; Melanocortin type 4 receptor agonists; Melanocortin type 4 receptor antagonists; Melanocortin type 5 receptor agonists; Melanocortin type 5 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cachexia; Diabetes mellitus; Dry eyes; Erythropoietic protoporphyria; Inflammation; Inflammatory bowel diseases; Kidney disorders; Nephritis; Obesity; Uveitis; Vitiligo

Most Recent Events

  • 28 Feb 2022 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (PO)
  • 30 Nov 2021 Palatin Technologies receives patent allowance for method of treating cytokine storm using melanocortin-specific peptide in USA in November 2021
  • 28 May 2020 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top